MBrace Therapeutics

MBrace Therapeutics, based in San Diego, CA, the United States, is a biotechnology company. MBrace Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer, using a proprietary in vivo target-discovery platform called SPARTA. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in prostate cancer, HR-positive / HER2-negative breast cancer, colorectal cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The largest, NCT07145255 (Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumours), plans to enrol 150 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.